The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Weekly Release  2004: Volume 8/ Issue 30 Article 5
Back to Table of Contents

Eurosurveillance, Volume 8, Issue 30, 22 July 2004

Citation style for this article: Walsh A, Morgan D. Differentiating inhalational anthrax from other influenza-like illnesses and acute respiratory infections in the setting of a deliberate release of Bacillus anthracis. Euro Surveill. 2004;8(30):pii=2510. Available online:

Differentiating inhalational anthrax from other influenza-like illnesses and acute respiratory infections in the setting of a deliberate release of Bacillus anthracis

Amanda Walsh ( and Dilys Morgan, Health Protection Agency Communicable Disease Surveillance Centre, London, UK

Many acute respiratory illnesses are viral in aetiology, and the infections are broadly grouped together as influenza-like illness (ILI) because of the similarity in presenting symptoms. Community acquired pneumonia (CAP) is often bacterial and frequently requires hospitalisation. Depending on the disease stage at presentation, inhalational anthrax (IA) may have features of either ILI or CAP. Recognition of inhalational anthrax, particularly amongst seasonal acute respiratory illnesses, is likely to be difficult if a deliberate release has not been recognised.

The classic clinical picture of IA is biphasic but non-specific, with an initial phase that is influenza-like with fever, malaise, myalgia and cough. The second phase begins abruptly with development of an acute dyspnoea and progresses rapidly to septic shock. The non-specificity of the early symptoms may make it unrealistic to diagnose in the absence of a known release, but prompt recognition is critical for appropriate management.

Two recent papers have attempted to define those clinical features that may assist diagnosis, and to develop a diagnostic algorithm [1,2]. Following recognition of a release or of other cases, a risk assessment is crucial with patients being assigned to a high risk or no risk group based on their exposure to anthrax spores. Not all potential cases will be encountered in such a setting, however, and certain groups, especially the elderly, are particularly vulnerable, since infection may result from exposure to a very low dose of spores [3]. Sporadic cases will require differentiation from other more common causes of acute respiratory illness, including CAP. Table 1 shows those signs and symptoms likely to be most useful for distinguishing clinical syndromes.

Table 1. Suggestive signs and symptoms for inhalation anthrax. (Adapted from references 1 and 2.)

Symptoms/test results favouring possible inhalation anthrax
  Widened mediastinum on CXR or CT scan
  Pleural effusions
  Haemoconcentration >50%
  Shortness of breath
  Chest discomfort or pleuritic chest pain
  Drenching sweats
  Nausea or vomiting
  Oxygen saturation <94% by pulse oximeter
  PaO2 <70mmHg on room air
  Elevated transaminases
Symptoms/test results favouring other influenza-like illness
  Sore throat
  Positive rapid tests for influenza or RSV

The following scoring systems have also been used to aid the differentiation of clinical presentations.

Table 2. Scoring system to distinguish between IA and ILI. (Adapted from reference 2.)

Low serum albumin +2
Tachycardia +2
No nasal symptoms +2
No myalgia or arthralgia +1
Low serum sodium +1
No headache +1
High haematocrit or haemoglobin +1

A score of ≥ 4 was 100% sensitive and 96% specific for IA

Table 3. Scoring system to differentiate IA from CAP. (Adapted from reference 2.)

Elevated serum ALT and AST levels +1
Low serum sodium level +1
Normal WBC count +1
Nausea or vomiting +1
Tachycardia +1

However this only poorly differentiates IA from CAP: Score ≥ 2, sensitivity100% but 48% specificity; Score ≥ 3, sensitivity 82%, specificity 81%.

The figure shows diagnostic investigations and outcomes for patients presenting with appropriate clinical signs/symptoms during an anthrax outbreak

Figure. Workup for patients with an ILI during an anthrax outbreak. (Reproduced with permission from reference 1.)

Key for algorithm:
ABGT - arterial blood gases
CBCD – complete blood count and differential
CR - chest radiograph
CSF – cerebrospinal fluid
CT - computed tomographic
GS - gram stain
IA – inhalational anthrax
IV – intravenous
LFTs – liver function tests
RSV respiratory syncytial virus

Following the recognition of a deliberate release of Bacillus anthracis, discrimination of IA from ILI could be readily achieved with high sensitivity and specificity. However differentiation from CAP, particularly that due to Streptococcus pneumoniae, is more problematic due to the fact that symptoms of each are generally indicative of sepsis. Recognition of the first cases of IA in a deliberate release is likely to remain problematic. An assessment of the known exposure or possible epidemiological risk may assist, but hospital admission and full diagnostic imaging, biochemical and microbiological investigations are required for definitive diagnosis.

  1. Cinti SK, Saravolatz L, Nafziger D, Sunstrum J, Blackburn G. Differentiating inhalational anthrax from other influenzalike illnesses in the setting of a national or regional anthrax outbreak. Arch Intern Med 2004;64:674-6. ( [accessed 7 July 2004. Subscription required]
  2. Kuehnert MJ, Doyle TJ, Hill HA, Bridges CB, Jernigan JA, Dull PM, et al. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis 2003;36:328-36. ( [accessed 7 July 2004]
  3. Inglesby TV, O’Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Anthrax as a biological weapon 2002: Updated recommendations for management. JAMA 2002:287;2236-52

back to top

Back to Table of Contents

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.